Roth Capital analyst, Yasmeen Rahimi, reiterated her Buy rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) after the company announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE